EA Pharma Co., Ltd.

EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Chuo-ku, Tokyo, Japan) (hereinafter “EA Pharma”) announced today that EA Pharma has entered in to an agreement to invest Remiges BioPharma Fund II, LP (hereinafter “Fund”), established by Remiges Ventures (President, Taro Inaba, offices in Tokyo, Boston and Seattle), up to10 million dollars cumulatively.

As a gastrointestinal specialty pharma, EA Pharma is focused on ”inflammatory bowel disease”, “liver and pancreatic diseases”, “gastrointestinal function and symptoms improvement”, “gastrointestinal mucosal protection” and “supports for gastrointestinal endoscopy/surgery” and aims to provide pharmaceuticals, medical devices and other solutions for the disease areas with high unmet medical needs.

EA Pharma expects to build up a strong network between the venture companies having early stage seeds in Japan, North America, Europe, Israel and other regions to bring innovations unique to EA Pharma. In addition, EA Pharma dispatches its employees to Regimes Ventures to cultivate global-level human resources having a keen sense for discovery.
EA Pharma aims to continually contribute to patients suffering from gastrointestinal diseases, their families and healthcare providers in the world.

■ About the Fund

End